Concepedia

Igor Tartakovsky

IT

12

Publications

518

Citations

11

H-Index

2009

Active since

Affiliations

Boehringer Ingelheim (United States)(Current)

Heidelberg University

Boehringer Ingelheim (Germany)

University of Alberta

University of Mannheim

Igor Tartakovsky is an author at Boehringer Ingelheim (United States) specializing in medicine, hematology, and thrombosis.

Top concepts

MedicineHematologyThrombosisDementiaNeurologyTreatmentPediatricsPharmacologyPharmacotherapyPharmacokinetics

Publications per year

2009–2021

12

Publications

12

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Leonardo R. Brandão, Matteo Luciani, Lisa Bomgaars et al. · The Lancet Haematology · 2020 · 134 citations · Full text

Thrombosis, Venous Disease, Venous Thrombosis +8

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

Leonardo R. Brandão, Manuela Albisetti, Lisa Bomgaars et al. · Blood · 2019 · 90 citations · Full text

Efficacy and tolerability of Ginkgo biloba extract EGb 761® by type of dementia: Analyses of a randomised controlled trial

Oleksandr Napryeyenko, Grigoriy Sonnik, Igor Tartakovsky · Journal of the Neurological Sciences · 2009 · 79 citations

Neurodegenerative Diseases, Alzheimer's Disease, Dementia +5

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program

John Fanikos, Debra Murwin, Fredrik Gruenenfelder et al. · Thrombosis and Haemostasis · 2019 · 47 citations · Full text

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability

Jacqueline ML Halton, Manuela Albisetti, Branislav Biss et al. · Journal of Thrombosis and Haemostasis · 2017 · 34 citations · Full text

Rows per page

1–5 of 12